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and placebo periods, patients were randomized into 5 groups for 3 weeks: 
placebo, Mib 25/50 rag, 501100 rag, 100/150 mg or amlodipine (Am) 5/10 mg. 
In addition, ET duration and duration of daily silent ischemia improved 
significantly only by Mib 50/100 and 100/150 rag. Both Mib and Am were well 
tolerated. 
Conclusion: Mibefradil given once daily is a highly effective in suppressing 
exercise and daily ischemia, 
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~ T h e  of  Exercise Capacity in the Importance 
Interpretation o f  an Ischeml¢ Response to Exercise 
Testing 
John R Murphy, Michael G. Kahn, Ronald J. Krone. MMIR Group 
Washington Univereily School of Medicine, St. Louis, MO 
We sought o determine the influence of exercise capacity on risk stratification 
in patients with positive exercise thallium tests. The pdmary trial (Muificentar 
Myocardial Ischemia Research Group) of 936 patients with stable coronary 
artery disease who had exercise thallium testing and were followed for 23 
months has already been reported. We stratified patients by beth ECG 
results and exercise capacity, and baseline variables were compared among 
groups. Kaplan-Malar event curves were calculated for the primary outcome, 
the combination of unstable angina, myocardial infarction, or cardiac death. 
For event cuwes for patients stratified by ECG results and stage three, p 
= 0.0004. For patients stratified by overall thallium result and stage 3, p 
= 0.0083. Seen below, the combination of both a positive test and limited 
exercise capacity predicts inoreesed risk. 
Event rate, ECG 1 yr 2 yr Event rate, Thallium I yr 2 Yr 
Positive, < $3 23°/. 33% Positive. < S3 20% 28% 
Positive, ~ $3 9% 13% Positive, > $3 11% 19% 
Negative, < $3 11% 16% Negative, < $3 10% 17% 
Negative, >_ $3 14% 19% Negative, > $3 13% 17% 
Event rates for patients with a positive ECG or thallium test but able to 
reach stage 3 are not different from those of patients with negative ECG 
and thallium tests, Thus, preserved exercise capacity identifies patients at 
low dsk for cardiac events despite an ischercio response to exercise thallium 
testing. 
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~'~- - ]  Cost Implications for Treatment of Cardiac 
Ischemla: An Ancil lary AsymptomaticCardlac 
Isehemla Pilot (ACIP) Study 
Cad J. Pepine, Daniel Mark, Martial Bourassa, Bemard Chairman, 
Geneil Knatterud, Sandra Forman, Craig Pratt, George Bopko, C. 
Richard Conti. Universily of Florida, Gainesville, FL 
Economic implications for ischemia management were studied in 558 pts 
randomized to one of three initial treatment strategies (aegina-guided in = 
183] or Ischemia-gulded (n= 183] medical care or revasculadzation i  = 192]). 
Cost data for events and procedure-related hospitalizations were assigned 
using Medicare diagnosis-related-group (DRG) reimbursement rates in 1993 
dollars, As expected, resource consumption for the initial yr of care was 
considerably higher with revascularization ($13,030) compared with angina- 
and Ischemie-gutded medical strate@es ($4,265 and $4,692/pt enrolled). 
There were significantly more nonprotocol revescuierization procedures and 
events in the medical strategies compared with revascularization, so cost/pt 
for the last 6 rags of the first yre care was greater for the medical strategies 
($1,314 and $2,074) than ravasoularization ($204). If these costs differences 
can be extrapolated through future follow-up yrs then the costs of medical 
strategies could reasWexceeq costs of revasoularization in 4 to 6 yre because 
of the expense of additional events in the medical strategies. 
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Thus revesculadzation may prove, with additional follow-up, to be cost 
effective or even cost saving relative to an initial medical strategy to manage 
ischemla. 
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~ - ~  Combination Therapy With Metoprolo l  and 
Nifedipine Doesn't Have Addit ive AntHschemic 
Effect in individual Patients With Stable Angina 
Pectoris 
Stefano Savonitto, Diego Ardissir,o, Kenneth Egstrup, Inger Wahlqvist, 
Piera A. Madini, Nina Rehnqvist. Milan, Italy for the IMAGE study group 
It is not dear whether combined therapy with metoprolol (M) (which reduces 
oxygen consumption) and nlfediplne (N) (which increases coronary flow) has 
an additive effect in 10Is with stable angina. In a double blind trial 280 pts 
were enrolled in 25 European Centers. After a 2-week placebo (PI) (wk 0), 
10ts were randomtsod to M 200 mg o.d. or N 20 mg b.Ld. for 6 wks; then, they 
randomly added PI or the altsmative drag for a further 4 wks. Exercise tests 
were performed at wks 0, 6 and 10. 248 patients completed the study. At wk 
6, M increased time to -1 mm ST depression (TST) by 70" (95% CI 47 to 
92") in comparison with wk 0, and N by 43" (16 to 69) (both p < 0.01 vs wk 
0; p < 0.05 M vs N). At wk 10, those pts adding PI did not change their mean 
exercise tolerance further, while those adding N to M had a further increase 
(p < 0.05 vs PI) to achieve a gain of 108" (71 to 145") from wk 0, and those 
adding M to N achieved a gain of 107" (64 to 151 ") from wk 0 (p < 0.C5 vs PI). 
However, this mean additive effect of combined therapy was not due to an 
additive effect in individual pts. In fact, only 6% of the pts in the M + N group 
and 6% in the N + M group increased TaT >_ 15% of their basaline value 
both dudng monotherapy anddudng combined therapy, vs 6% in the M ÷ PI 
group and 3% in the N + PI group (all p = ns). Moat of the additive effect in 
the combination groups was due to a "recruitment" of responders (increase 
in TaT > 15°/@ from the value at wk 6) by the 2nd drug when the 1st had 
been ineffective: 10% with M + N, 25% with N + M (p < 0.05 vs N + PI), 12°/@ 
with M + PI and 10% with N + PI. Thus, in a group of pts with stable angina, 
combined therapy with M and N improves exercise tolerance compared with 
monotherapy. However, this effect is not due to an additive effect in individual 
lOtS, but to a "recruitment" of tots non responders to monotherapy. 
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~"6"~"[  Randomized Trial o f  AnUdepreesants In Patients 
With lachemlc Heart Disease 
Mitchell S. Finkal, Andrew Gaffney, Pouzia Laghfissi-Thode, Bruce 
G. Pollock, John Kennedy, Craig Nelson, Ivan Gergel, James R McCaffedy, 
Stevon R Roo~;e. Univemity of Pittsburgh, Pittsburgh, PAl Vanderbilt 
University, Nashville, TN 
Clinical depression following myocardial infarction has recently been identi- 
fied as an independent risk factor for subsequent cardiac death. The Cardiac 
Arrhythmia Suppression Trial raised serious concerns about the use of tri- 
cyclic antidepressants 0"CA) in patients with ischemic heart disease (IHD) 
in view of their Class IA antiarrhythmio properties. Little systematic data are 
available on the cardiac effects of selective serotonin reuptaKe inhlbifore 
($SRI). Accordingly, we conducted the first prospective, randomized, clinical 
trial of the safety and efficacy of the SSRI, Paroxetlne (Px), and the TCA, 
Norldptyline (Nt), in IHD. 41 IHO patients received Px and 40 Nt for treat- 
ment of clinical depression based on a Hamilton Depression Scale (HAM-O) 
score of > 17. Over 80% of the patients in both groups were taking cardiac 
medications including beta blockers and espldn. Antidepressant efficacy was 
similar in both groups with 73% of Nt and 66% of Px patients achieving > 
50% reduction in HAM-D over the 6 week study period. Supine pulse rates 
increased from 70:1= 2 to 78 ± 2 in Nt patients with no ch~.nge in Px patients 
(66 ± 2 vs. 66 a- 1). 37/41 Px and 26/40 Nt completed week 6. 8/40 Nt and 
2/41 Px were withdrawn due to adverse events, including 7 Nt cardiac events 
despite optimal blood levels (unstable angina, dysrhythmie) end 1 Px with 
palpitations. We conclude that depressed patients with IHD can be effectively 
treated with either Nt or Px. However, Px appears to be better tolerated with 
fewer adverse cardiac effects in IHD. 
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{"7~'- 1 -~ Natural History of  Hypertrophic Cardlomyopathy 
During Childhood Revisited in an Unselectsd 
Community-Based Populat ion 
David A. Burton, Liviu C. Pollac, Barry J. Maron. Children's Heart Clinic and 
Minneapolis Heart Institute Foundation, Minneapolis, MN 
Clinical course of hypertrophic cardiomyopathy (HCM) in childhood has been 
